Please ensure Javascript is enabled for purposes of website accessibility

The Two Reasons Why Illumina Rose 8.3% In April

By Brian Feroldi – May 10, 2017 at 6:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A new product launch and upbeat first-quarter results caused Illumina's stock to rally.

What happened

Illumina (ILMN -1.39%), a leading provider of genetic testing equipment, gained 8.3% during the month of April according to data from S&P Global Market Intelligence

So what

Here's a review of the key events from April that helped drive the company's share price higher:

  • Illumina launched the VeriSeq NIPT Solution in Europe. This product will provide Europeans with a noninvasive prenatal test that can screen for chromosomal abnormalities in as little as one day.
  • Illumina reported pleasing first-quarter results. Sales jumped 4.5% to $598 million, which came in above management's guidance range and topped Wall Street's expectation. Adjusted EPS fell 9.9% to $0.64, but that was mostly owed to a higher tax rate. This figure matched what market watchers had predicted.
  • CEO Francis deSouza stated that the company received more than 135 orders in the first quarter for its new NovaSeq products.
  • Management guided for second-quarter revenue to grow around 7% and for non-GAAP earnings to land between $0.65 to $0.70. The midpoint of the company's EPS guidance range represents another year-over-year decline. However, Wall Street was predicting a decline, so this guidance didn't surprise the markets..

These upbeat announcements caused traders to bid up the company's share price. 

picture of an illumina Hi-Sex X system

Image Source: Illumina.

Now what

Illumina believes that its revenue and profits will grow by double-digits in 2017 as customers begin to upgrade to the company's NovaSeq platform. However, management warned investors that near-term profits will likely be negatively impacted by higher costs associated with the launch. That's a trade-off that long-term investors should be happy to see since the NovaSeq series promises to keep the company one step ahead of competitors such as Pacific Biosciences of California and Thermo Fisher Scientific. With 135 orders booked in the first quarter alone, Illumina's NovaSeq platform looks like it has a bright future ahead.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Illumina. The Motley Fool recommends Pacific Biosciences of California. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Illumina Stock Quote
Illumina
ILMN
$218.99 (-1.39%) $-3.09
Pacific Biosciences of California Stock Quote
Pacific Biosciences of California
PACB
$10.11 (-2.32%) $0.24
Thermo Fisher Scientific Stock Quote
Thermo Fisher Scientific
TMO
$551.25 (0.72%) $3.96

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.